Get regular updates to your inbox.
The first patient has been dosed in the resumed Phase 2a clinical trial of montelukast for mild to moderate Alzheimer’s disease. IntelGenx, the company running the study known as BUENA (NCT03402503), suspended the trial in late 2020 due to…
Read more
The National Institutes of Health (NIH) awarded $2 million to investigators studying how chronic physiological stress may cause vascular changes and exacerbate the cognitive decline seen in Alzheimer’s disease. Paul Chantler, PhD, an associate professor at West Virginia University School of…
3K3A-APC, an investigational therapy for stroke about to enter Phase 3 clinical testing, may also help to protect the brain against Alzheimer’s disease and other forms of dementia. “Our recent and current data support development of 3K3A-APC for neurological conditions associated…
The U.S. Food and Drug Administration (FDA) has put a clinical hold Denali Therapeutics’ application to begin clinical testing of DNL919, an immune-modulating medication that the company is developing to treat Alzheimer’s disease. The FDA will issue an official clinical…
Amyloidosis brings many hardships, writes columnist Jaime Christmas, but what matters is facing them with strength and resilience.
Check out FAP News Today’s collection of Health Insights, where you can find a variety of information for patients and caregivers.
Becoming educated and informed about FAP is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your FAP journey.
There is no cure for FAP yet, but there are treatments that can help manage the disease. Learn more about the approved and experimental therapies here.
Get regular updates to your inbox.